News Orexo AB OTC Markets

Equities

Delayed OTC Markets Other stock markets 18:39:53 24/06/2024 BST			5-day change	1st Jan Change
2 ^USD	+16.28%		-9.50%	+32.45%

05-08	Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024
05-08	Orexo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Orexo : Presentation	06-25	PU
Orexo : Life Science Investor Forum US, June 20 (Presentation)	06-13	PU
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm	05-10	AQ
Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024	05-08
Orexo Q1 2024 Interim Report	05-08	AQ
Orexo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Fentanyl awareness day: The synthetic opioid fentanyl increasingly poisons young Americans	05-07	PU
Orexo : Invitation to presentation of Orexo´s Q1 2024 Interim Report	05-02	PU
Report from Orexo AB's annual general meeting, 26 April 2024	04-26	AQ
Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	04-17	MT
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US	04-17	AQ
Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US	04-17	CI
Sweden's Orexo Set for Early Redemption of Bonds Due 2025	04-02	MT
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled	04-02	AQ
Orexo publishes the Annual and Sustainability Report for 2023	03-28	AQ
Orexo AB Announces Board Resignations	03-22	CI
Correction: Notice of Annual General Meeting of Orexo	03-15	AQ
Notice of Annual General Meeting of Orexo	03-15	AQ
Orexo Issues SEK500 Million Social Bonds, Closes Tender Offer	03-14	MT
Orexo Issues Senior Secured Callable Floating Rate Social Bonds of SEK 500 Million and Announces Results of the Tender Offer for Its Existing Bonds	03-13	CI

No results for this search